Skip to content

colchicine in heart failure

Assessment of anti-inflammatory treatment with colchicine in patients with chronic heart failure with reduced left ventricular ejection fraction

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20240617062161N1
Enrollment
64
Registered
2024-07-20
Start date
2024-07-22
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic and non-ischemic heart failure with reduced ejection fraction (less than 40%). Heart failure

Interventions

Intervention 1: Intervention group: ischemic and non-ischemic heart failure patients with reduced ejection fraction (less than 40%) who receive colchicine at a dose of 0.5 mg for 3 months in addition

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: chronic heart failure with reduced left ventricular ejection fraction(40%>) The diagnosis of heart failure with reduced ejection fraction has been confirmed at least one year ago At least for 3 months under standard medical treatment Stable and compensated clinical conditions

Exclusion criteria

Exclusion criteria: Acute cardiac ischemic event within a year before or during the study Getting cancer Not taking regular medications in the previous 3 months Acute myocarditis Acute pericarditis Suffering from other chronic inflammatory diseases such as vascular collagen diseases or infectious diseases Heart surgery in the last 6 months Cerebral vascular events during the last 6 months Patients who need colchicine due to other diseases (such as gout) History of colchicine intolerance

Design outcomes

Primary

MeasureTime frame
Hs-CRP plasma level. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: kit test.

Secondary

MeasureTime frame
Interleukin 6 plasma level. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: kit test.;Pro-BNP plasma level. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: Kit test.;NHA functional class. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: NHA functional class questionnaire.;6MWT. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: Measuring tape.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAsal Yadollahi

Mashhad University of Medical Sciences

Yadollahia@mums.ac.ir0095 5138012739

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026